Literature DB >> 26838996

Successful Treatment of a Pacemaker Infection with Intraperitoneal Daptomycin.

Anne B Taegtmeyer1, Nina Kononowa2, Dominique Fasel3, Manuel Haschke4, Felix Burkhalter5.   

Abstract

We investigated the pharmacokinetics of intraperitoneal administration of daptomcyin in a peritoneal dialysis (PD) patient treated for a pacemaker infection with Staphylococcus epidermidis. After initial start of intravenous daptomycin at 9 mg/kg body weight every 48 hours, the therapy was switched to intraperitoneal administration of 5.3 mg/kg body weight in 1 L icodextrin 7.5% with a dwell time of 12 hours overnight every 48 hours. Therapeutic drug monitoring (TDM) was performed at 4 hours and 24 hours after dose administration. Due to high peak concentration above target peak concentration, the dose was reduced to a final maintenance dose of 3.2 mg/kg body weight. Data from this single case suggest that serum drug concentration above the minimal inhibitory concentration (MIC) can be easily achieved with intraperitoneal administration of daptomycin every 48 hours even with a lower dose, as recommended for the intravenous administration, but measurement of serum concentration and dose adjustments are mandatory in such cases.
Copyright © 2016 International Society for Peritoneal Dialysis.

Entities:  

Keywords:  Intraperitoneal; daptomycin; peritoneal dialysis

Mesh:

Substances:

Year:  2016        PMID: 26838996      PMCID: PMC4737578          DOI: 10.3747/pdi.2014.00271

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  12 in total

1.  Peritoneal dialysis-related infections recommendations: 2010 update.

Authors:  Philip Kam-Tao Li; Cheuk Chun Szeto; Beth Piraino; Judith Bernardini; Ana E Figueiredo; Amit Gupta; David W Johnson; Ed J Kuijper; Wai-Choong Lye; William Salzer; Franz Schaefer; Dirk G Struijk
Journal:  Perit Dial Int       Date:  2010 Jul-Aug       Impact factor: 1.756

2.  Comparative in vitro antimicrobial activity of vancomycin, teicoplanin, daptomycin and ceftobiprole in four different peritoneal dialysis fluids.

Authors:  S Tobudic; W Poeppl; C Kratzer; A Vychytil; H Burgmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-19       Impact factor: 3.267

3.  Daptomycin compatibility in peritoneal dialysis solutions.

Authors:  Laure Peyro Saint Paul; Françoise Albessard; Cathy Gaillard; Danièle Debruyne; Jean-Philippe Ryckelynck; Antoine Coquerel; Thierry Lobbedez
Journal:  Perit Dial Int       Date:  2011 Jul-Aug       Impact factor: 1.756

4.  Simultaneous quantitation of azole antifungals, antibiotics, imatinib, and raltegravir in human plasma by two-dimensional high-performance liquid chromatography-tandem mass spectrometry.

Authors:  Jean-François Jourdil; Julia Tonini; Françoise Stanke-Labesque
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2013-01-09       Impact factor: 3.205

5.  Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis.

Authors:  Sujata M Bhavnani; Christopher M Rubino; Paul G Ambrose; George L Drusano
Journal:  Clin Infect Dis       Date:  2010-06-15       Impact factor: 9.079

6.  Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis.

Authors:  H Albin; J M Ragnaud; F Demotes-Mainard; G Vinçon; M Couzineau; C Wone
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model.

Authors:  Elizabeth D Hermsen; Laurie B Hovde; John R Hotchkiss; John C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

8.  Increased peritoneal permeability in patients with peritonitis undergoing continuous ambulatory peritoneal dialysis.

Authors:  M E McIntosh; W G Smith; B J Junor; G Forrest; M J Brodie
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

9.  In vivo pharmacodynamic activity of daptomycin.

Authors:  Nasia Safdar; David Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

Review 10.  Treatment of enterococcal peritonitis with intraperitoneal daptomycin in a vancomycin-allergic patient and a review of the literature.

Authors:  James F Gilmore; Miae Kim; Mary T LaSalvia; Monica V Golik Mahoney
Journal:  Perit Dial Int       Date:  2013 Jul-Aug       Impact factor: 1.756

View more
  2 in total

1.  Newer antibiotics for the treatment of peritoneal dialysis-related peritonitis.

Authors:  Terry King-Wing Ma; Chi Bon Leung; Kai Ming Chow; Bonnie Ching-Ha Kwan; Philip Kam-Tao Li; Cheuk Chun Szeto
Journal:  Clin Kidney J       Date:  2016-07-04

Review 2.  Impact on Antibiotic Resistance, Therapeutic Success, and Control of Side Effects in Therapeutic Drug Monitoring (TDM) of Daptomycin: A Scoping Review.

Authors:  Carolina Osorio; Laura Garzón; Diego Jaimes; Edwin Silva; Rosa-Helena Bustos
Journal:  Antibiotics (Basel)       Date:  2021-03-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.